Jiangsu Recbio Gets HKEX Approval for Hong Kong Share Full Circulation
MT Newswires Live
Feb 09
Jiangsu Recbio Technology (HKG:2179) said the Hong Kong Stock Exchange has granted listing approval for its Hong Kong share full circulation application, according to a Feb. 6 bourse filing.
The approval covers the conversion of about 142 million unlisted shares into Hong Kong-listed shares.
The converted shares represent about 22.67% of the company's total issued share capital.
Upon completion of the conversion, Jiangsu Recbio's H-shares will increase to about 458.1 million, accounting for roughly 73.17% of total issued shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.